Oric Pharmaceuticals, Inc. - Common Stock par value $0.0001 per share (ORIC)
CUSIP: 68622P109
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock par value $0.0001 per share
- Shares outstanding
- 104,331,515
- Total 13F shares
- 119,653,820
- Share change
- +12,268,927
- Total reported value
- $979,579,552
- Put/Call ratio
- 0%
- Price per share
- $8.18
- Number of holders
- 165
- Value change
- +$96,243,084
- Number of buys
- 98
- Number of sells
- 55
Quarterly Holders Quick Answers
What is CUSIP 68622P109?
CUSIP 68622P109 identifies ORIC - Oric Pharmaceuticals, Inc. - Common Stock par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 68622P109:
Top shareholders of ORIC - Oric Pharmaceuticals, Inc. - Common Stock par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13D/G
13F
|
Company |
10%
|
8,729,345
|
$95,149,860 | +$23,507,430 | 30 Jun 2025 | |
| Nextech Invest, Ltd. |
13F
|
Company |
6.9%
|
7,162,637
|
$85,951,644 | — | 30 Sep 2025 | |
| EcoR1 Capital, LLC |
13F
13D/G
|
Company |
6.9%
from 13D/G
|
6,728,116
|
$80,737,392 | — | 30 Sep 2025 | |
| VR Adviser, LLC |
13F
|
Company |
6.3%
|
6,596,885
|
$79,162,620 | — | 30 Sep 2025 | |
| Nextech Crossover I GP S.a r.l. |
13D/G
|
— |
8.4%
|
7,162,637
|
$78,072,743 | $0 | 30 Jun 2025 | |
| PFIZER INC |
13F
3/4/5
|
Company · 10%+ Owner |
5.2%
|
5,376,344
|
$64,516,128 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.6%
from 13D/G
|
5,276,620
|
$63,319,440 | — | 30 Sep 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
5.8%
|
5,676,230
|
$57,556,972 | -$9,335,442 | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.5%
|
4,650,138
|
$55,801,656 | — | 30 Sep 2025 | |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
|
Company |
4.3%
|
4,514,929
|
$54,179,148 | — | 30 Sep 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
4.6%
|
4,504,096
|
$54,049,152 | $0 | 30 Sep 2025 | |
| SR ONE CAPITAL MANAGEMENT, LLC |
13D/G
|
— |
4.8%
|
4,615,384
|
$50,307,686 | $0 | 12 Aug 2025 | |
| NEA Management Company, LLC |
13F
|
Company |
3.9%
|
4,118,621
|
$49,423,452 | — | 30 Sep 2025 | |
| COLUMN GROUP II, LP |
13D/G
3/4/5
|
Peter Svennilson · 10%+ Owner |
3.7%
|
3,644,118
|
$48,612,534 | $0 | 30 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
3.5%
|
3,641,756
|
$43,701,072 | — | 30 Sep 2025 | |
| Column Group LLC |
13F
|
Company |
3.4%
|
3,540,777
|
$42,489,324 | — | 30 Sep 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
3%
|
3,126,604
|
$37,519,248 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.8%
|
2,871,327
|
$34,457,000 | — | 30 Sep 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
5.1%
from 13D/G
|
2,619,914
|
$31,438,968 | — | 30 Sep 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
3.5%
from 13D/G
|
2,528,048
|
$30,336,576 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.3%
|
2,403,939
|
$28,847,268 | — | 30 Sep 2025 | |
| First Turn Management, LLC |
13F
|
Company |
2.1%
|
2,159,474
|
$25,913,688 | — | 30 Sep 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
1,948,808
|
$23,385,696 | — | 30 Sep 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.7%
|
1,729,378
|
$20,752,536 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
1,630,744
|
$19,573,783 | — | 30 Sep 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.5%
|
1,519,314
|
$18,231,768 | — | 30 Sep 2025 | |
| ROYCE & ASSOCIATES LP |
13F
|
Company |
1.4%
|
1,458,483
|
$17,501,796 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.2%
|
1,228,528
|
$14,742,336 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.1%
|
1,198,004
|
$14,376,048 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.1%
|
1,181,329
|
$14,175,948 | — | 30 Sep 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
1.1%
|
1,097,497
|
$13,169,964 | — | 30 Sep 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
0.97%
|
1,007,575
|
$12,090,900 | — | 30 Sep 2025 | |
| Euclidean Capital LLC |
13F
|
Company |
0.95%
|
989,410
|
$11,872,920 | — | 30 Sep 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.91%
|
951,507
|
$11,418,056 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.87%
|
904,812
|
$10,857,744 | — | 30 Sep 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.86%
|
900,000
|
$10,800,000 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.85%
|
888,535
|
$10,662,420 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.76%
|
793,871
|
$9,523,125 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.71%
|
745,528
|
$8,946,336 | — | 30 Sep 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
James N. Topper |
2%
|
1,410,193
|
$7,981,692 | $0 | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.58%
|
603,207
|
$7,238,484 | — | 30 Sep 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.45%
|
468,610
|
$5,623,320 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.43%
|
447,366
|
$5,368,392 | — | 30 Sep 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.41%
|
431,693
|
$5,180,316 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.33%
|
339,236
|
$4,070,832 | — | 30 Sep 2025 | |
| SECTORAL ASSET MANAGEMENT INC |
13F
|
Company |
0.32%
|
328,655
|
$3,943,860 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.24%
|
246,534
|
$2,958,408 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.23%
|
238,620
|
$2,863,440 | — | 30 Sep 2025 | |
| Nicholas Investment Partners, LP |
13F
|
Company |
0.21%
|
220,735
|
$2,648,820 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.18%
|
184,091
|
$2,209,092 | — | 30 Sep 2025 |
Institutional Holders of Oric Pharmaceuticals, Inc. - Common Stock par value $0.0001 per share (ORIC) as of Q4 2025
As of 31 Dec 2025,
Oric Pharmaceuticals, Inc. - Common Stock par value $0.0001 per share (ORIC) was held by
165 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
119,653,820 shares.
The largest 10 holders included
Nextech Invest, Ltd., EcoR1 Capital, LLC, VIKING GLOBAL INVESTORS LP, BlackRock, Inc., VR ADVISER, LLC, Pfizer Inc, VANGUARD GROUP INC, SR One Capital Management, LP, ALKEON CAPITAL MANAGEMENT LLC, and STATE STREET CORP.
This page lists
165
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
151
Q4 2025 holders
165
Holder diff
14
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.